ArticleAmerican journal of translational research2025
Rabeprazole- and vonoprazan-based dual therapies for H pylori eradication: effective with low side effects, rabeprazole being more cost-effective.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breaking barriers in the first-lineWorld journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the eradication effect of dual therapy based on rabeprazole or vonoprazan for
methodsData from 300 Hp-positive patients were retrospectively analyzed. Patients who received rabeprazole and amoxicillin were assigned to the rabeprazole group, those who received vonoprazan and amoxicillin were placed in the vonoprazan group, and those who underwent conventional quadruple therapy (omeprazole + amoxicillin + clarithromycin + bismuth potassium citrate) were included in the control group. Clinical medical records, including baseline characteristics, symptom manifestations, examination results, treatment regimens, and treatment costs, were collected. The Hp eradication rate, symptom relief, levels of inflammatory markers (interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP)), incidence of adverse reactions, treatment compliance, and cost-effectiveness ratio (C/E) were compared among the three groups.
resultsIn both per-protocol (PP) and intention-to-treat (ITT) analyses, no statistically significant differences were observed in eradication rates among the three groups (P>0.05). Symptom relief was more pronounced at 44 days of treatment compared to 14 days across all groups (P<0.05). At both 14 and 44 days, significant differences were found in the relief of abdominal distension (14 days: Z=20.644, P<0.001; 44 days: Z=11.577, P=0.003) and belching (14 days: Z=23.234, P<0.001; 44 days: Z=20.194, P<0.001) among the three groups (P<0.05), with the rabeprazole group showing the best improvement, followed by the control group. After treatment, the IL-6, TNF-α, and CRP levels in the rabeprazole and vonoprazan groups were lower than those in the control group (all P<0.05). There was no significant difference in treatment compliance among the three groups (χ
conclusionDual therapy based on rabeprazole or vonoprazan effectively improves symptoms in patients with Hp infection, with relatively few adverse reactions and good treatment compliance. Additionally, rabeprazole-based dual therapy had a lower cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.